User Fee Delinquencies Rising At US FDA After PDUFA Redesign
Executive Summary
Prescription drug user fee "receivables" nearly doubled in FY 2018, but the US FDA is not worried.
You may also be interested in...
PDUFA VII: FDA, Industry Agree To Set Minimum Carryover Balance Levels
The minimum total will increase from eight weeks of operating expenses in FY 2023 to 10 weeks by FY 2025.
US Biosimilar Fee Collections Fall Short
A lower-than-expected number of fee-paying application submissions in FY 2018 resulted in the agency spending approximately $9.7m more than anticipated from its user fee carryover balance, leading to a reset of spend-down targets for the remainder of BsUFA II.
After Biosimilar Fee Collections Fall Short, US FDA Modifies Carryover Spend-Down Plan
A lower-than-expected number of fee-paying application submissions in FY 2018 resulted in the agency spending approximately $9.7m more than anticipated from its user fee carryover balance, leading to a reset of spend-down targets for the remainder of BsUFA II.